PEMF Therapy

How PEMF Works

PEMF is the only modality on this site that doesn’t require electrode contact with the skin. Instead of delivering electrical current directly through the body, PEMF generates a pulsed magnetic field around a coil or pad. When that field passes through tissue, it induces a weak electrical current inside the cells themselves — a process called electromagnetic induction.

This is the same principle Michael Faraday described in 1831: a changing magnetic field creates an electric field in any conductor it passes through. Biological tissue is a conductor. So a pulsed magnetic field, applied externally, gently induces current in cells without any direct contact needed.

That induced current then interacts with two key biological systems:

• Ion channels and membrane potential — The electromagnetic field activates voltage-gated calcium channels in cell membranes, triggering downstream signaling cascades that influence inflammation, tissue repair, and cellular metabolism.¹⁵
• Adenosine receptors — Multiple studies by Varani et al. have shown PEMF upregulates A2A and A3 adenosine receptors on immune cells, producing measurable anti-inflammatory effects via a pathway that does not depend on current density or ion channel activation alone.^16,17

Because the field passes through skin, fat, and bone before reaching target tissue, PEMF can reach deep structures — joints, vertebrae, organs — that direct-contact microcurrent cannot easily access. This is one of PEMF’s key practical advantages over electrode-based therapies.

FDA Approval and a Brief History

PEMF has the strongest regulatory history of any modality on this site. The FDA cleared PEMF for the stimulation of bone repair in 1979 — over 45 years ago — based on consistent evidence from C. Andrew Bassett and colleagues at Columbia University, who demonstrated that pulsed electromagnetic fields reliably stimulate osteogenesis in nonunion fractures that had failed to heal with conventional treatment.¹

The work was replicated in a double-blind clinical trial by Sharrard (1990), which found PEMF significantly accelerated healing of delayed tibial fractures versus sham.² More recently, Hannemann et al. (2014) published a randomized controlled trial showing favorable clinical and radiological outcomes for acute scaphoid fractures treated with PEMF.³

Additional FDA clearances have followed for cervical fusion adjuncts and urinary incontinence. The bone healing indication remains the best-established and most frequently cited. Everything else on this page — pain, inflammation, sleep, tissue repair — sits in a different evidence tier and should be understood separately from the bone healing approval.

What the Research Shows

Chronic Pain and Osteoarthritis

A 2009 systematic review by Vavken et al. evaluated the evidence for PEMF in knee osteoarthritis and found a statistically significant effect on pain and function across included trials, concluding that PEMF was a safe adjunct for managing knee OA symptoms.⁴ A 2020 meta-analysis by Li et al. examined data from multiple randomized controlled trials and reported meaningful improvements in pain scores and functional outcomes with PEMF versus sham.⁵

These are not case series or observational studies — they are systematic reviews of RCT data, which places this evidence at Tier 2 with real confidence behind it. The honest caveat: study quality across individual trials is variable, and effect sizes are moderate rather than dramatic.

Postoperative Recovery and Angiogenesis

Tepper et al. (2004) published a controlled study in Circulation Research demonstrating that electromagnetic fields increase angiogenesis — the formation of new blood vessels — both in cell culture and in an animal model. Vascular endothelial growth factor (VEGF) expression was significantly elevated in PEMF-treated specimens compared to controls.⁶

Callaghan et al. (2008) found that PEMF significantly accelerated wound healing in both normal and diabetic animal models, with histological evidence of improved collagen organization and capillary density in treated wounds.¹⁸ Markov’s 2007 review provides helpful historical context on how PEMF applications in wound healing developed from the bone healing literature.⁷

Inflammation and Neurological Effects

Ross and Harrison’s 2013 systematic review of electromagnetic fields and inflammation identified consistent anti-inflammatory effects across included studies, noting that the mechanism appears to operate through adenosine receptor upregulation rather than direct thermal effects.⁸ Rohde et al. (2010) found that PEMF significantly reduced IL-1β levels and postoperative pain in a controlled study of patients following surgery.⁹

Cartilage, Connective Tissue, and Chondrocytes

De Mattei et al. (2007) demonstrated that PEMF stimulation significantly increased human chondrocyte proliferation and extracellular matrix synthesis in cell culture — including aggrecan and type II collagen production, the structural components of healthy cartilage.¹⁴ This mechanistic evidence is relevant context for the pain and OA clinical trials above, as it suggests a biological pathway for the observed effects rather than purely symptomatic relief.

Water Structure and Biofield Hypotheses

Gerald Pollack’s work on structured water (“the fourth phase of water”) proposes that water near biological surfaces forms an exclusion zone (EZ) with distinct electrical properties that may interact with electromagnetic fields.¹⁹ Rubik’s biofield hypothesis and McCraty’s work on cardiac coherence extend this framework into proposals about how biological systems generate and respond to electromagnetic information.^20,21

These are scientific hypotheses with early supporting evidence — not established mechanisms. I present them at Tier 4 with the explicit caveat that they represent the frontier edge of inquiry, not proven science. They are relevant here because they inform the rationale behind frequency-specific PEMF applications, but they should not be interpreted as confirmation of any therapeutic claim.

PEMF Evidence at a Glance

The chart below maps PEMF applications against evidence strength. Bar height represents evidence quality. Applications are grouped by clinical domain.

Key Research Summary

Standard PEMF vs. Frequency-Specific PEMF

Not all PEMF devices work the same way, and this distinction matters for understanding what Resonance Health Hub recommends and why.

Field Intensity: Does µT Level Matter?

One of the most common questions about PEMF devices is whether the field strength — measured in microtesla (µT) or millitesla (mT) — determines how effective the device will be. The honest answer is: intensity matters, but it’s only one of several parameters that collectively determine the biological response. Frequency, waveform, pulse shape, treatment duration, and tissue depth all interact with field strength in ways that no single number captures on its own.

That said, the research does give us useful context for thinking about where iCare (15 µT), the Infopathy Glow Pad (500 µT), and Vibe PEMF (900 µT) each sit relative to what the science has studied.

What the Research Shows on Intensity

Clinical trials have used a wide range. A comprehensive review of in vivo PEMF studies found that intensities used in published research ranged from 35 µT at the low end to 30 mT (30,000 µT) at the high end, with most bone healing and orthopedic studies using 1–12 mT.^4,9 This means both iCare and the Infopathy Glow Pad sit at the lower end of what most clinical research has formally studied for joint and bone applications.

Ultra-low intensity can still produce cellular responses. One peer-reviewed study exposed cultured human chondrocytes to PEMF at just 1.95 µT — well below even iCare’s 15 µT — and found significant improvements in cell viability, extracellular matrix production, and chondrocyte proliferation at 0.1 Hz over 60-minute daily sessions for 3 consecutive days.²⁴ A separate in vitro study exposed fibroblast and endothelial cells to 100 µT PEMF and demonstrated progressive reduction in oxidative stress markers after 8 days of daily 30-minute sessions.²² These findings establish that cellular-level responses are possible at very low field strengths — particularly with extended exposure durations.

Higher intensity reduces the time needed to achieve a response. A comparative study on arthritis treatment found that NSAID use was 26% in patients using a 1,500 µT device for 6 hours per day, versus 75% in patients using a 15 µT device on the same schedule — suggesting the lower-intensity group needed substantially longer exposure to achieve comparable symptom support, or may not have reached target tissue at the same depth.²³ For deeper tissues like hip joints (requiring 8–12 cm of penetration), some researchers note that very low intensity fields may not deliver sufficient charge to the target tissue, regardless of duration.²³

How This Applies to iCare, Infopathy, and Vibe PEMF

Devices Used at Resonance Health Hub

iCare PEMF Platform — 15 µT, Frequency-Specific, Overnight Use

The iCare Platform delivers FSM frequency pairs via PEMF at 15 µT. It is a wellness-positioned device — intentionally not FDA-cleared, which is what makes it accessible without a practitioner prescription. Foundational frequency packages are available to all users; custom programming beyond those packages is done in consultation with a practitioner. iCare’s primary clinical advantage is extended overnight use: the app runs FSM protocols while you sleep, allowing cumulative daily exposure that longer-duration, lower-intensity research supports as a meaningful pathway to cellular response. Available through Max’s practitioner pathway.

Infopathy + Glow Pad — 500 µT, Multi-Modal, Self-Directed

The Infopathy platform pairs with the Glow Pad to deliver FSM-compatible frequencies at 500 µT — a meaningfully stronger field than iCare for localized, focused sessions. Infopathy is fully self-customizable from the IC library: no consultation or prescription required for any level of use. Beyond PEMF, the platform also delivers blue, red, and near-infrared light therapy, audio-based frequency delivery, and water imprinting — making it the most multi-modal wellness device in this category. Both devices are wellness tools, not FDA-cleared medical devices; that positioning is intentional and is what makes them accessible. For a detailed comparison of iCare and Infopathy, see the iCare vs. Infopathy page.

Vibe PEMF (Resona Health) — 900 µT, Standard PEMF, Wearable

The Vibe PEMF by Resona Health is a pocket-sized standard PEMF device delivering up to 900 µT — the highest field intensity of any device on this page. Unlike iCare and Infopathy, it uses standard PEMF with pre-programmed protocols rather than FSM frequency pairs. It requires no app, no subscription, and no practitioner involvement: 60+ built-in protocols across pain, sleep, inflammation, stress, and recovery are accessible immediately. Worn in a shirt pocket or around the neck on the included lanyard, it’s designed for continuous passive use during daily activity. Affiliate link with disclosure on the Shop page.